The currently recruiting NOA-21 trial (NCT03893903) aims to assess safety and efficacy of combining IDH1-vac with the programmed death-ligand 1 (PD-L1) inhibitor Avelumab in recurrent glioma. Here, IDH1 is linked to central nervous system cancer.